Effects of YM-14673, a new thyroid-releasing hormone analogue, on neurological deficits in stroke-prone spontaneously hypertensive rats.

Abstract

The effects of YM-14673, a new thyroid-releasing hormone (TRH) analogue (N alpha-[[(S)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide dihydrate), on neurological deficits were examined in stroke-prone spontaneously hypertensive rats (SHRSP). The neurological deficits were evaluated for more than 21 days after stroke. Administration of YM-14673 was started the day stroke was observed and repeated daily for 3 weeks. YM-14673 (0.1 and 0.3 mg/kg i.p.) improved the neurological deficits and reduced mortality. These results demonstrate that YM-14673 mitigates cerebral ischemic changes in SHRSP.

• Authors: M Yamamoto, K Sudoh, M Sasamata
• Journal: European journal of pharmacology (Eur J Pharmacol) Vol. 192 Issue 1 Pg. 165-7 (Jan 03 1991) ISSN: 0014-2999 [Print] Netherlands
• PMID: 2040359 (Publication Type: Journal Article)

Chemical References

• Azetidines
• Dipeptides
• azetirelin

Topics

• Animals
• Azetidines (pharmacology)
• Blood Pressure (drug effects)
• Cerebrovascular Disorders (genetics, physiopathology)
• Dipeptides (pharmacology)
• Male
• Nervous System Diseases (etiology, physiopathology)
• Psychomotor Performance (drug effects)
• Rats
• Rats, Inbred SHR